JMA Journal
Online ISSN : 2433-3298
Print ISSN : 2433-328X
Review Article: COVID-19
Case Management of COVID-19 (Secondary Version)
Yasuyuki Kato
Author information
JOURNAL OPEN ACCESS

2021 Volume 4 Issue 3 Pages 191-197

Details
Abstract

Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts.

Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups.

Content from these authors
© 2021 Japan Medical Association

JMA Journal applies the Creative Commons Attribution License to all works published by the journal. Anyone may download, reuse, copy, reprint, distribute, or modify articles published in the journal, if they cite the original authors and source. No permission is required from the publisher.
http://creativecommons.org/licenses/by/4.0/
Previous article Next article
feedback
Top